Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.34 |
| ▸ | TK1 | P04183 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034685 | 0.89 | ASAH1 (0.45) | ASAH1METALDH1A1KDM4ETK1 | |
| SCHEMBL26034726 | 0.87 | ALDH1A1 (0.39) | CA1CA2GFERALDH1A1KDM4E | |
| SCHEMBL26035406 | 0.86 | CA1 (0.41) | ASAH1CA1CA2TK1TSHR | |
| SCHEMBL26034615 | 0.86 | CA1 (0.41) | ASAH1CA1CA2TK1TSHR | |
| SCHEMBL26039881 | 0.83 | MET (0.38) | ASAH1METGFERALDH1A1KDM4E | |
| SCHEMBL26064067 | 0.83 | MET (0.36) | ASAH1METGFERALDH1A1KDM4E | |
| SCHEMBL26039626 | 0.81 | ASAH1 (0.42) | ASAH1METCA1CA2TK1 | |
| SCHEMBL24205206 | 0.79 | POLB (0.41) | ASAH1METCA1CA2GFER | |
| SCHEMBL24205211 | 0.77 | CYP2C9 (0.46) | ASAH1CA1CA2TK1TSHR | |
| SCHEMBL26035362 | 0.77 | CYP2C9 (0.46) | ASAH1CA1CA2TK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | ASAH1 1148/4885MET 4772/4885CA1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.